suppl. fig. 2

Suppl. Fig. 2

Cntrl

FasL25ng/ml

A

Pro-caspase 3

Actin

B

Cntr

l

zVA

D

0.5

FasL

25 F

asL

HuT

78

0.5

FasL

+zV

AD

25 F

asL

+zVA

D

Cntr

l

0.5

FasL

5 Fa

sL

25 F

asL

Cntr

l

α-Fa

s

25 F

asL

+α-F

as

zVA

D

25

FasL

+ zV

AD

Cntr

l

0.5

FasL

0.5

FasL

+zV

AD

25 F

asL

zVA

D

25 F

asL+

zVA

D

day 1 day 2 day 4 day 6day 6

35 KDa

43 KDa

Evaluation of FasL-induced apoptosis in BM-MSCs.A) BM-MSCs were plated on chamber slides at a density of 5×103 cells/cm2 and treated with 25 ng/ml FasL for 1, 2, 4, or 6 days. After fixation they were stained with Hoechst to show nuclei (arrows, pycnotic nuclei). B) Original caspase 3 western blots from batch # 1 BM-MSCs treated with 0.5 ng/ml FasL (0.5 FasL), 25 ng/ml FasL (25 FasL), or pretreated with the caspase inhibitor zVAD before FasL treatment (0.5 FasL zVAD, 25 FasL zVAD). Untreated cells (cntrl) and zVAD-supplemented cells (zVAD) were used as controls. HuT78 cell line treated with 25ng/ml FasL for 5 hours were used as caspase-3 activation positive control.

19/17 KDaactive fragments